Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Recruiting now

Conditions studied: Baseline Thrombocytopenia

In brief

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Key facts

Study ID

NCT06223607

Run by

Methodist Health System

People needed

300

Starts

2022-08-22

Expected to finish

2027-12-22

Last updated by the study team

2026-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years
• PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
• Thrombocytopenia defined as platelet count <100 x103 /µL on at least one occasion prior to PCI
• At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor

You may not qualify if…

• Death within 48 hours post-PCI
• DAPT prior to cardiac catheterization

Where it is running

• Methodist Dallas Medical Center — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.